Euroopan unioni - suomi - EMA (European Medicines Agency)

a. menarini industrie farmaceutiche riunite s.r.l. - delafloxacin meglumiini - yhteisön hankkimat infektiot - systeemiset bakteerilääkkeet, - quofenix is indicated for the treatment of the following infections in adults:acute bacterial skin and skin structure infections (absssi),community-acquired pneumonia (cap), when it is considered inappropriate to use other antibacterial agents that are commonly recommended for the initial treatment of these infections (see sections 4. 4 ja 5. on otettava huomioon viralliset ohjeet antibioottien tarkoituksenmukaisesta käytöstä.

Suomi - suomi - Fimea (Suomen lääkevirasto)

baxter oy - aspartic acid, glutamic acid, alanine, arginine, calcium chloride dihydrate, glucose monohydrate, aminoacetic acid, histidine, isoleucine, potassium chloride, leucine, lysine acetate, phenylalanine, proline, serine, threonine, tryptophane, tyrosine, valine, magnesium chloride hexahydrate, sodium acetate trihydrate, soya-bean oil, refined, olive oil, refined, sodium glycerophosphate hydrate - infuusioneste, emulsio - yhdistelmävalmisteet

Suomi - suomi - Fimea (Suomen lääkevirasto)

fresenius kabi ab - histidine, lysine acetate, threonine, tryptophane, tyrosine, alpha-ketoleucine calcium, alpha-ketophenylalanine calcium, alpha-ketovaline calcium, d,l-alpha-hydroxymethionine calcium, d,l-alpha-ketoisoleucine calcium - tabletti, kalvopäällysteinen - aminohapot

Euroopan unioni - suomi - EMA (European Medicines Agency)

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - rokotteet - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. käyttö tämä rokote tulee virallisten suositusten mukaisesti.

Euroopan unioni - suomi - EMA (European Medicines Agency)

bayer ag - octocog alfa - hemofilia a - hemostaatit - verenvuodon hoito ja ehkäisy hemofilia a-potilailla (synnynnäinen tekijä viii puutos). iblias voidaan käyttää kaikille ikäryhmille.

Euroopan unioni - suomi - EMA (European Medicines Agency)

bayer ag  - octocog alfa - hemofilia a - hemostaatit - verenvuodon hoito ja ehkäisy potilailla, joilla on hemofilia a (synnynnäinen tekijä viii -häiriö). tämä valmiste ei sisällä von willebrand-tekijää ja on näin ollen ei ole tarkoitettu von willebrandin taudin hoitoon.

Euroopan unioni - suomi - EMA (European Medicines Agency)

cipla (eu) limited - olantsapiini - schizophrenia; bipolar disorder - psyykenlääkkeiden - adultsolanzapine on tarkoitettu skitsofrenian hoitoon. olantsapiini on ylläpitää tehokkaasti kliinistä paranemista aikana, jatkoa hoito potilailla, jotka ovat osoittaneet ensimmäisen hoitovasteen. olantsapiini on tarkoitettu keskivaikean tai vaikean maanisen jakson. potilailla, joiden maaninen episodi on vastannut olanzapine hoito, olantsapiini on osoitettu uusiutumisen ehkäisyyn potilailla, joilla on kaksisuuntainen mielialahäiriö.

Suomi - suomi - Fimea (Suomen lääkevirasto)

fresenius kabi ab - aspartic acid, glutamic acid, alanine, arginine, calcium chloride dihydrate, glucose monohydrate, aminoacetic acid, histidine, isoleucine, potassium chloride, leucine, methionine, phenylalanine, proline, serine, threonine, tryptophane, tyrosine, valine, lysine hydrochloride, magnesium sulfate heptahydrate, sodium acetate trihydrate, sodium glycerophosphate anhydrous, soya oil - infuusioneste, emulsio - yhdistelmävalmisteet

Suomi - suomi - Fimea (Suomen lääkevirasto)

b. braun melsungen ag - magnesii acetas tetrahydricum,prolinum,valinum,soiae oleum,argininum,acidum asparticum,glucosum monohydricum,methioninum,alaninum,phenylalaninum,serinum,natrii dihydrogenophosphas dihydricus,natrii chloridum,tryptophanum,leucinum,isoleucinum,zinci acetas dihydricus,histidini monohydrochloridum monohydratum,acidum glutamicum,lysini hydrochloridum,kalii acetas,triglycerida saturata media,threoninum,natrii acetas trihydricus,calcii chloridum dihydricum,natrii hydroxidum,acidum aminoaceticum - infuusioneste, emulsio - yhdistelmävalmisteet

Suomi - suomi - Fimea (Suomen lääkevirasto)

b. braun melsungen ag - acidum asparticum,leucinum,magnesii acetas tetrahydricum,natrii chloridum,triglycerida saturata media,soiae oleum,acidum glutamicum,valinum,serinum,lysini hydrochloridum,natrii hydroxidum,threoninum,calcii chloridum dihydricum,natrii acetas trihydricus,tryptophanum,phenylalaninum,alaninum,natrii dihydrogenophosphas dihydricus,zinci acetas dihydricus,kalii acetas,argininum,isoleucinum,histidini monohydrochloridum monohydratum,glucosum monohydricum,prolinum,methioninum,acidum aminoaceticum - infuusioneste, emulsio - yhdistelmävalmisteet